/ /

Advances

Dupilumab demonstrates promising resultsThe systemic therapy dupilumab met primary endpoints in two phase 3 studies on adults with in inadequately controlled moderate-to-severe atopic dermatitis.
Lessons from the past
Lessons from the pastScientists are digging into the past in search of genetic insight into modern skin diseases. Here are some of the hottest topics in the study of human history and skin disease.
FDA approves first once-monthly injection to lower cholesterolFDA approved evolocumab (Repatha, Amgen) Pushtronex system, the first monthly single-dose injection of a PCSK9 inhibitor. Repatha was already approved by FDA as the only PCSK9 inhibitor with a monthly dose last August.
Critical factors in healing acute woundsOptimal wound healing practices have changed in recent years. some techniques are no longer best practice and new techniques have emerged.
Study exposes inaccuracy of new test for Lyme diseaseLooks like marketing and publicity might have outpaced the validity and usefulness of a test used to detect Lyme disease.
FDA approves cannabis-derived drugFor the first time, FDA approved dronabinol oral solution (Syndros, Insys Therapeutics), a liquid formulation of the pharmaceutical cannabinoid dronabinol, a pharmaceutical version of tetrahydrocannabinol ("THC").
Cheaper hep C drug enters competitive market
Cheaper hep C drug enters competitive marketA new drug approved by FDA to treat chronic hepatitis C virus (HCV) infection this week enters a competitive, lucrative market headed up by Gilead Science’s Sovaldi and Harvoni, as well as AbbVie’s Viekira Pak. FDA granted priority review and breakthrough therapy designation to Gilead’s combination product, Epclusa (sofosbuvir 400 mg/velpatasvir 100 mg).

Poll

View Results